Abera Bioscience AB (NGM:ABERA)

Sweden flag Sweden · Delayed Price · Currency is SEK
9.20
+1.15 (14.29%)
At close: Jul 16, 2025
104.90%
Market Cap112.07M
Revenue (ttm)15.93M
Net Income (ttm)-729.00K
Shares Out15.35M
EPS (ttm)-0.05
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume34,581
Average Volume11,171
Open8.90
Previous Close8.05
Day's Range8.10 - 9.30
52-Week Range3.51 - 9.70
Beta1.09
RSI48.49
Earnings DateAug 18, 2025

About Abera Bioscience AB

Abera Bioscience AB, a platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally. The company’s development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead vaccine candidate is a universal pneumococcal vaccine based on the platform BERA. The company also develops projects in immuno-oncology, Chlamydia, ETEC,... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2012
Employees 5
Stock Exchange Nordic Growth Market
Ticker Symbol ABERA
Full Company Profile

Financial Performance

In 2024, Abera Bioscience AB's revenue was 14.63 million, an increase of 479.60% compared to the previous year's 2.52 million. Losses were -1.10 million, -93.42% less than in 2023.

Financial Statements

News

There is no news available yet.